Clinical Development Program Shows Promise for Microbiome-Based Therapeutics in Recurrent C. Diff

Lindy Bancke, PharmD, head of clinical development at Rebiotix Inc, said the clinical development program of RBX2660 is showing promise in the treatment of recurrent C. Difficile infection.

In an interview with Pharmacy Times, Lindy Bancke, PharmD, head of clinical development at Rebiotix Inc, said the clinical development program of RBX2660 is showing promise in the treatment of recurrent C. Difficile infection.

In the discussion, Bancke talked about how RBX2660 compared to previous treatment options, the link between the gut microbiome and C. diff, the impressive sustained clinical response success rate from the development program, and complementary findings from the PUNCH CD3 trial.